RxDoctor Payments Data

Lamonica Harrison, PA

Physician Assistant · Cypress, TXNPI 1053824573

Payments from drug & device makers

$5,760in general payments, 2019–2025

Across 310 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$843
  • Novo Nordisk$725
  • Lilly USA, LLC$428
  • AstraZeneca$428
  • Biohaven Pharmaceuticals, Inc.$317
  • Boehringer Ingelheim$307
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$5,760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,760 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$74,757
Medicare patients
196
Services billed
2,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$62,144
JardianceEmpagliflozin46$58,943
FarxigaDapagliflozin Propanediol68$54,207
MounjaroTirzepatide37$37,664
XifaxanRifaximin12$35,801
EliquisApixaban11$18,606
TrulicityDulaglutide11$14,891
LinzessLinaclotide12$14,718
Repatha SureclickEvolocumab14$8,819
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,369
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,238
SymbicortBudesonide/Formoterol Fumarate11$3,827
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,347
Aripiprazole40$2,671
Levothyroxine Sodium194$1,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$428$65,27290 claims
Novo NordiskOzempic$725$62,14438 claims
Boehringer IngelheimJardiance$307$58,94346 claims
Lilly USA, LLCMounjaro, Trulicity$428$52,55448 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$103$35,80112 claims
PfizerEliquis$236$18,60611 claims
AbbVieLinzess$843$14,71812 claims
GSKTrelegy Ellipta, Shingrix$154$11,71528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →